Key result
Intracoronary adiponectin cuts myocardial infarct size ~45% vs. placebo in a porcine model.
Why the study?
Reperfusion injury remains an important limitation of myocardial revascularization, and the influence of intracoronary adiponectin on reperfusion injury and cardiomyocyte death was evaluated.
Does intracoronary adiponectin administered prior to reperfusion reduce infarct size in a porcine model of acute myocardial infarction?
Does intracoronary adiponectin administered prior to reperfusion reduce infarct size in a porcine model of acute myocardial infarction?
Intracoronary administration of adiponectin immediately before reperfusion safely and significantly reduces infarct size and preserves left ventricular ejection fraction in a porcine model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Intracoronary adiponectin reduced infarct size in pigs; leaves open translation to human reperfusion protocols.
Reperfusion injury (RI) remains an important limitation of myocardial revascularization. The aim of the present study was to evaluate the influence of the intracoronary injection of adiponectin on RI and cardiomyocyte death in a porcine myocardial infarction model. Acute infarction in 14 Polish domestic pigs was induced by inflation of an over the wire balloon (OTW) catheter in the medial left anterior descending artery for 60 min. The study group consisted of 7 pigs in which intracoronary adiponectin (50 µg) was infused through the OTW catheter immediately before reperfusion. The control group (n=7) was administered placebo. Animals were sacrificed after two days of follow-up. The infarct area (IA) was stained with tetrazoline and the area at risk (AAR) with intracoronary administration of Evans Blue dye before euthanasia. Hearts in each group had similar AARs (46.2±9.9% vs. 48.4±6.2% of the whole myocardium, p=ns). The IA/AAR% and IA were smaller in the study group when compared to the control (24.7±4.0% vs. 45.3±22.5%, p=0.005; and 11.7±4.9% vs. 20.5±5.6%, p=0.01, respectively). These outcomes corresponded well with the peak troponin levels after 12 h (109.9±60.9 ng/ml vs. 185.5±39.4 ng/ml, p=0.017). After two days there was a significantly higher LVEF in the study group (51.4±8.5% vs. 33.9±8.6%, p=0.002). There was also a trend toward lower apoptosis enhancement in the viable myocardium in the study group (3.11±2.3 vs. 8.92±6.3; p=0.07). The administration of adiponectin into the infarct- related artery is safe and feasible. The treatment significantly reduced the infarct size.
No takes yet. Share an insight, caveat, or question.
Marcin Dębiński (2011) studied Myocardial infarction (n=14). Intracoronary adiponectin vs. Placebo (saline) was evaluated on Infarct area as a percentage of area at risk (IA/AAR%) (p=0.005). Intracoronary administration of adiponectin immediately before reperfusion significantly reduced infarct size compared to placebo (24.7% vs. 45.3% of area at risk, p=0.005) in a porcine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: